Genetic susceptibility testing for Alzheimer disease: Motivation to obtain information and control as precursors to coping with increased risk

被引:51
作者
Gooding, Holly C.
Linnenbringer, Erin L.
Burack, Jeffrey
Roberts, J. Scott
Green, Robert C.
Biesecker, Barbara B.
机构
[1] Univ Calif Berkeley, Sch Publ Hlth, Div Community Hlth & Human Dev, Berkeley, CA 94720 USA
[2] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02215 USA
[3] Boston Univ, Sch Med, Dept Med, Genet Program, Boston, MA 02215 USA
[4] Boston Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02215 USA
[5] NHGRI, Social & Behav Res Branch, NIH, Bethesda, MD 20892 USA
关键词
genetic testing; genetic counseling; Alzheimer disease risk; apolipoprotein E; appraisals of health threat;
D O I
10.1016/j.pec.2006.03.002
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Objective: This study investigated appraisals, including motivation, and coping preferences for undergoing Apolipoprotein E (APOE) susceptibility testing for Alzheimer disease (AD). Methods: Participants were 60 adult children of individuals affected with AD enrolled in a trial investigating use and impact of APOE susceptibility testing. An exploratory qualitative study was undertaken in which participants were interviewed about their testing experience. Results: Most participants viewed genetic testing as providing valuable information that could help direct future health care decisions and meet their emotional concerns about living at increased risk. Participants related their motivation for genetic testing to their worries about developing AD, preference to seek information about health threats, and need to feel in control of their health. Results: Most participants viewed genetic testing as providing valuable information that could help direct future health care decisions and meet their emotional concerns about living at increased risk. Participants related their motivation for genetic testing to their worries about developing AD, preference to seek information about health threats, and need to feel in control of their health. Conclusion: Even without prevention or treatment options, genetic testing may be a useful coping strategy for some at-risk individuals. Practice implications: Once testing becomes clinically available, practitioners need to address the value and limitations of testing as well as appraisals and efforts to cope. (c) 2006 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:259 / 267
页数:9
相关论文
共 29 条
[1]  
[Anonymous], 2001, J Am Geriatr Soc, V49, P225
[2]  
[Anonymous], 1995, JAMA, V274, P1627
[3]   Stress and genetic testing for disease risk [J].
Baum, A ;
Friedman, AL ;
Zakowski, SG .
HEALTH PSYCHOLOGY, 1997, 16 (01) :8-19
[4]   Physicians' propensity to offer genetic testing for Alzheimer's disease: Results from a survey [J].
Chase, GA ;
Geller, G ;
Havstad, SL ;
Holtzman, NA ;
Bassett, SS .
GENETICS IN MEDICINE, 2002, 4 (04) :297-303
[5]   The psychological impact of genetic testing for Alzheimer disease [J].
Coon, DW ;
Davies, H ;
McKibben, C ;
Gallagher-Thompson, D .
GENETIC TESTING, 1999, 3 (01) :121-131
[6]   Estimating risk curves for first-degree relatives of patients with Alzheimer's disease: The REVEAL study [J].
Cupples, LA ;
Farrer, LA ;
Sadovnick, AD ;
Relkin, N ;
Whitehouse, P ;
Green, RC .
GENETICS IN MEDICINE, 2004, 6 (04) :192-196
[7]   Predictive testing for Huntington's disease: a challenge for persons at risk and for professionals [J].
Evers-Kiebooms, G ;
Decruyenaere, M .
PATIENT EDUCATION AND COUNSELING, 1998, 35 (01) :15-26
[8]   The psychological complexity of predictive testing for late onset neurogenetic diseases and hereditary cancers: implications for multidisciplinary counselling and for genetic education [J].
Evers-Kiebooms, G ;
Welkenhuysen, M ;
Claes, E ;
Decruyenaere, M ;
Denayer, L .
SOCIAL SCIENCE & MEDICINE, 2000, 51 (06) :831-841
[9]   Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease - A meta-analysis [J].
Farrer, LA ;
Cupples, LA ;
Haines, JL ;
Hyman, B ;
Kukull, WA ;
Mayeux, R ;
Myers, RH ;
PericakVance, MA ;
Risch, N ;
vanDuijn, CM .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1997, 278 (16) :1349-1356
[10]  
Folkman S, 2000, PSYCHO-ONCOL, V9, P11, DOI 10.1002/(SICI)1099-1611(200001/02)9:1<11::AID-PON424>3.0.CO